South Africa Alzheimers Therapeutics Market Size & Outlook

The alzheimers therapeutics market in South Africa is expected to reach a projected revenue of US$ 34.0 million by 2030. A compound annual growth rate of 13.1% is expected of South Africa alzheimers therapeutics market from 2023 to 2030.
Revenue, 2022 (US$M)
$12.7
Forecast, 2030 (US$M)
$34.0
CAGR, 2023 - 2030
13.1%
Report Coverage
South Africa

South Africa alzheimers therapeutics market highlights

  • The South Africa alzheimers therapeutics market generated a revenue of USD 12.7 million in 2022 and is expected to reach USD 34.0 million by 2030.
  • The South Africa market is expected to grow at a CAGR of 13.1% from 2023 to 2030.
  • In terms of segment, cholinesterase inhibitors was the largest revenue generating drug class in 2022.
  • Combination Drugs is the most lucrative drug class segment registering the fastest growth during the forecast period.


Alzheimers therapeutics market data book summary

Market revenue in 2022USD 12.7 million
Market revenue in 2030USD 34.0 million
Growth rate13.1% (CAGR from 2022 to 2030)
Largest segmentCholinesterase inhibitors
Fastest growing segmentCombination Drugs
Historical data2018 - 2021
Base year2022
Forecast period2023 - 2030
Quantitative unitsRevenue in USD million
Market segmentationCholinesterase inhibitors, NMDA Receptor Antagonist, Combination Drugs
Key market players worldwideEisai Co Ltd, Novartis AG ADR, AbbVie Inc, H. Lundbeck AS Class A, Biogen Inc, Roche Holding AG ADR, Daiichi Sankyo Co Ltd, Johnson & Johnson, AC Immune SA


Other key industry trends

  • In terms of revenue, South Africa accounted for 0.3% of the global alzheimers therapeutics market in 2022.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Middle East & Africa, Saudi Arabia alzheimers therapeutics market is projected to lead the regional market in terms of revenue in 2030.
  • South Africa is the fastest growing regional market in Middle East & Africa and is projected to reach USD 34.0 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Alzheimers Therapeutics Market Companies

Name Profile # Employees HQ Website

South Africa alzheimers therapeutics market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to alzheimers therapeutics market will help companies and investors design strategic landscapes.


Cholinesterase inhibitors was the largest segment with a revenue share of 52.76% in 2022. Horizon Databook has segmented the South Africa alzheimers therapeutics market based on cholinesterase inhibitors, nmda receptor antagonist, combination drugs covering the revenue growth of each sub-segment from 2018 to 2030.


South Africa is the largest market for Alzheimer’s therapeutics in the African continent. Increasing geriatric population and rising awareness about Alzheimer’s in the country are driving treatment rate among the people living with AD.

Around 750,000 people in South Africa are living with dementia. However, awareness about Alzheimer’s is limited in the country. Hence, to raise awareness, some organizations such as Alzheimer’s South Africa are focusing on reducing the risk and prevalence of this disease.

These organizations create public awareness and support by providing education & training programs to the people. South African government is working to improve access to effective medical treatments. The country has introduced price control measures such as capped annual price of expensive drugs.

Reasons to subscribe to South Africa alzheimers therapeutics market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of South Africa alzheimers therapeutics market databook

  • Our clientele includes a mix of alzheimers therapeutics market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the South Africa alzheimers therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into South Africa alzheimers therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

South Africa alzheimers therapeutics market size, by drug class, 2018-2030 (US$M)

South Africa Alzheimers Therapeutics Market Outlook Share, 2022 & 2030 (US$M)

South Africa alzheimers therapeutics market size, by drug class, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more